Iovance Biotherapeutics Inc (NASDAQ:IOVA) has a beta value of 1.08 and has seen 1.17 million shares traded in the recent trading session. The company, currently valued at $1.12B, closed the recent trade at $3.40 per share which meant it gained $0.15 on the day or 4.77% during that session. The IOVA stock price is -318.53% off its 52-week high price of $14.23 and 6.47% above the 52-week low of $3.18. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.28 million shares traded. The 3-month trading volume is 9.62 million shares.
The consensus among analysts is that Iovance Biotherapeutics Inc (IOVA) is Buy stock at the moment, with a recommendation rating of 1.31. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.24.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Sporting 4.77% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IOVA stock price touched $3.40 or saw a rise of 7.1%. Year-to-date, Iovance Biotherapeutics Inc shares have moved -53.99%, while the 5-day performance has seen it change -1.02%. Over the past 30 days, the shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) have changed -13.14%. Short interest in the company has seen 67.3 million shares shorted with days to cover at 5.69.
Wall Street analysts have a consensus price target for the stock at $11.5, which means that the shares’ value could jump 70.43% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $17.0. In that case, then, we find that the latest price level in today’s session is -400.0% off the targeted high while a plunge would see the stock gain -76.47% from the levels at last check today.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
The company’s shares have lost -63.74% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 176.01%.
10 analysts offering their estimates for the company have set an average revenue estimate of 83.4M for the current quarter. 10 have an estimated revenue figure of 102.36M for the next ending quarter. Year-ago sales stood 715k and 31.11M respectively for this quarter and the next, and analysts expect sales will grow by 11,563.73% for the current quarter and 176.01% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.17% over the past 5 years.
IOVA Dividends
Iovance Biotherapeutics Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders own 0.63% of the company shares, while shares held by institutions stand at 84.05% with a share float percentage of 84.58%. Investors are also buoyed by the number of investors in a company, with Iovance Biotherapeutics Inc having a total of 405.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 25.95 million shares worth more than $208.12 million. As of 2024-06-30, VANGUARD GROUP INC held 9.7478% of shares outstanding.
The other major institutional holder is PERCEPTIVE ADVISORS LLC, with the holding of over 25.93 million shares as of 2024-06-30. The firm’s total holdings are worth over $207.98 million and represent 9.1052% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.63% shares in the company for having 8.61 shares of worth $29.74 million while later fund manager owns 7.06 shares of worth $24.39 million as of Feb 28, 2025, which makes it owner of about 2.15% of company’s outstanding stock.
